Psychedelics


Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

February 3rd, 2023 - Ryan Allway

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.   The Therapeutic Goods Administration (TGA) will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. These are […]

Irwin Naturals Secures $40 Million of Financing for its Current Operations including Psychedelic Mental Health Clinic Rollup, Potential for up to $60 Million

February 2nd, 2023 - Ryan Allway

LOS ANGELES, Feb. 02, 2023 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today that the Company has secured a credit facility as of February 1, 2023 with its existing commercial lender for up to $60 million with $40 million of it currently committed. The rate shall be variable […]

Kaya Holdings, Inc. (OTCQB:KAYS) Launches Fifth Dimension Therapeutics(TM) to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and address the Growing Multi-Billion Dollar Global Psychedelics Market

January 25th, 2023 - Ryan Allway

FT. LAUDERDALE, FL / ACCESSWIRE / January 25, 2023 / Kaya Holdings, Inc., (“KAYS” or the “Company”) (OTCQB:KAYS), a pioneer in the U.S. cannabis industry, announced today that it has launched Fifth Dimension Therapeutics™ (“FDT”), which will seek to provide psychedelic “mind care” treatments to veterans suffering from PTSD, addicts seeking to break addiction, individuals with […]

PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA

January 24th, 2023 - Ryan Allway

PharmAla Biotech believes that this is the largest export permit of MDMA granted to date by Health Canada   VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA) and its manufacturing partners […]

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

December 13th, 2022 - Ryan Allway

Clearmind Medicine Inc. (Nasdaq,CSE: CMND), (FSE: CWY) (“Clearmind” or the “company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, today announced it has completed IND-enabling studies on its CMND-100 (MEAI- based) compound aimed at  treating alcohol use disorder (AUD), in preparation for its first […]

The Addition of Three Mental Health Clinics to Irwin Naturals’ Florida Footprint Solidifies the Companies Impact as One of the Fastest-Growing Chains of Mental Health Clinics

December 9th, 2022 - Ryan Allway

Company continues to expand its national network of psychedelic mental-healthcare clinics   LOS ANGELES, Dec. 09, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of Clare Clinic, Inc., d/b/a Florida Mind Health Center.   The Company entered into an acquisition agreement (the “Agreement”) […]

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

December 7th, 2022 - Ryan Allway

MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan.   Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on […]

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine

December 1st, 2022 - Ryan Allway

ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. ( Nasdaq: SILO ) (“the Company”) , a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company’s progress and potential for its portfolio of novel, IP-protected technologies and assets developed in collaboration with world-class medical research partners. The […]

Irwin Naturals Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics

November 30th, 2022 - Ryan Allway

LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it reached a binding, arms-length, agreement to acquire Serenity Health, LLC in Louisville, Kentucky, on November 25, 2022. The move continues Irwin’s national ketamine clinic rollup strategy that has seen the Company move quickly toward its […]

Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin

November 16th, 2022 - Ryan Allway

Pharmaceutical Grade Psilocybin Synthesized By Mindset’s Patent Pending Process TORONTO, Nov. 16, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, and PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a […]

Tripsitter Clinic Ltd. Announces The Closing Of Assets Acquisition Deal With Reconcious Medial And Appointment Of Dr. Mark Braunstein As Chairman

November 11th, 2022 - Ryan Allway

TORONTO, Nov. 11, 2022 /CNW/ – TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter” or the “Company”), further to the press release dated Mar 22, 2022, today announced the closing of the acquisition of assets of Insight Systems, PBC doing business as Reconscious Medical.  The assets of Reconscious Medical will be instrumental in the future […]

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

November 10th, 2022 - Ryan Allway

KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company’s collaborators from the University of Michigan will present two scientific posters in the upcoming Society for […]

Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression

November 4th, 2022 - Ryan Allway

TORONTO, November 04, 2022–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company“) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce positive initial results from […]

harmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

November 2nd, 2022 - Ryan Allway

ALA-002 is PharmAla’s lead drug candidate, showing exceptional safety and efficacy in preclinical rodent models   VANCOUVER, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) — PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug Administration (USFDA) in advance of its pre-IND meeting […]

Silo Wellness Announces LOI for Potentially Largest Psilocybin Retreat Center in Oregon and the World – If November’s Election Is Favorable; and an Oregon Real Estate Law and Psilocybin Industry Primer

October 20th, 2022 - Ryan Allway

Springfield, Oregon–(Newsfile Corp. – October 20, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo Wellness” or the “Company”), Oregon’s only publicly traded psychedelics company, is pleased to announce it has executed a binding term sheet for a joint venture with New Frontier Ranch in the majestic Green Springs area of Jackson County Oregon, […]

Optimi Health Announces Closing Of Strategic Non-Brokered Private Placement

October 11th, 2022 - Ryan Allway

Chip Wilson expands current share position and commits gross proceeds of up to $3.27 million. Highlights: • $1.85 million in proceeds received through a strategic offering of units at $0.325 per unit with each unit comprised of one common share and one-half of one (1/2) Common Share purchase warrant exercisable at $0.50, for total potential […]

Emerald Announces the Launch of reMind: A New Business Resource for the Psychedelics Revolution

October 6th, 2022 - Ryan Allway

Dedicated to the advancement of breakthrough medicine and treatments in psychedelics, reMind will host its debut event — The Psychedelics Business Forum — at MJBizCon   NEW YORK, October 06, 2022–(BUSINESS WIRE)–Emerald Holding, Inc. (NYSE: EEX), today introduced reMind, a new media and events platform committed to building, connecting and educating diverse communities to responsibly grow the business of […]

Irwin Naturals Agrees to Add Idaho Clinic to Its National Chain of Psychedelic Mental-Health Clinics

October 4th, 2022 - Ryan Allway

Irwin Naturals Emergence announces acquisition agreement in Idaho, continuing national rollup of ketamine clinics   LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) has reached a binding agreement on September 30, 2022 to acquire Ketamine Infusions of Idaho, PLLC, which operates a clinic in Idaho […]

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

October 3rd, 2022 - Ryan Allway

Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments KELOWNA, British Columbia, Oct. 03, 2022 (GLOBE NEWSWIRE) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the World Intellectual Property Organization (WIPO) published their international […]

Silo Wellness Executes Definitive Agreement to Acquire Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio

September 27th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – September 27, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo Wellness” or the “Company”), a leading global psychedelics company, and Dyscovry Science Ltd. (“Dyscovry”), a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome, today announced the […]

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

September 27th, 2022 - Ryan Allway

Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO” ENGLEWOOD CLIFFS, NJ , Sept. 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public […]

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

September 22nd, 2022 - Ryan Allway

Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd.   VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major […]

Lobe Sciences Announces Closing of Private Placement

September 8th, 2022 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – September 8, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of units (the “Units”) for gross proceeds of […]

Irwin Naturals Emergence to Add Ohio Ketamine Clinic

September 6th, 2022 - Ryan Allway

Company announces agreement that will expand its national chain of health clinics into central Ohio   LOS ANGELES, Sept. 06, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today that it has entered into a binding to agreement to acquire all of the membership interests in Happier You, LLC, […]

Optimi Health Provides Progress Report On Year Of Commercialization

September 1st, 2022 - Ryan Allway

  Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise     VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus […]

PharmAla Biotech to supply University of Sydney Clinical Trial with LaNeo™️ MDMA

August 31st, 2022 - Ryan Allway

Second major clinical trial to select PharmAla Biotech as supplier since PharmAla become the first public company to manufacture GMP MDMA   VANCOUVER, August 31, 2022 (Canada Newswire) – PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the University of Sydney’s upcoming Phase 2 Clinical Trial. Founded in 1850, […]

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

August 25th, 2022 - Ryan Allway

VANCOUVER, British Columbia, Aug. 24, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders. ​ A recent study, published in Experimental Neurology, has provided some new evidence that LSD […]

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment

August 24th, 2022 - Ryan Allway

The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind’s MEAI   VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced […]

Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments

August 23rd, 2022 - Ryan Allway

Based on over 20 years of pioneering Yale University research, clinical development currently underway to create and develop viable and efficacious treatment alternatives for patients with major depressive disorder by leveraging the known pharmacology of ketamine and psychedelic-based therapeutics   SAN FRANCISCO, August 23, 2022–(BUSINESS WIRE)–Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious […]

Another Public Company First: Silo Wellness Opens Jamaican Ecotourism Psilocybin Microdosing Resort for the Psychedelic Curious; Shareholder Discounts for Psychedelic Vacations Available

August 23rd, 2022 - Ryan Allway

Springfield, Oregon–(Newsfile Corp. – August 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo Wellness” or the “Company”), a leading global psychedelics company, is pleased to announce that it has opened its first ecotourism microdosing psilocybin resort and retreat center at Go Natural Jamaica in Long Bay, Portland, Jamaica. “We have been bombarded […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading